MSCL.F Stock Overview
A biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Satellos Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.41 |
| 52 Week High | CA$0.58 |
| 52 Week Low | CA$0.22 |
| Beta | 1.17 |
| 11 Month Change | 7.94% |
| 3 Month Change | -8.36% |
| 1 Year Change | 11.76% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| MSCL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.2% | -1.6% | -0.06% |
| 1Y | 11.8% | 10.4% | 20.5% |
Return vs Industry: MSCL.F exceeded the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: MSCL.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| MSCL.F volatility | |
|---|---|
| MSCL.F Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MSCL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: MSCL.F's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Frank Gleeson | satellos.com |
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne.
Satellos Bioscience Inc. Fundamentals Summary
| MSCL.F fundamental statistics | |
|---|---|
| Market cap | US$42.69m |
| Earnings (TTM) | -US$15.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs MSCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSCL.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$13.82m |
| Gross Profit | -CA$13.82m |
| Other Expenses | CA$7.31m |
| Earnings | -CA$21.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MSCL.F perform over the long term?
See historical performance and comparison